Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$0.76
-$0.08(-1.39%)
At close: 4:00 PM EST
$0.76
-$0.08(-1.39%)
Day’s Range― - ―
52-Week Range$3.74 - $2,841.00
Previous CloseN/A
Volume40.32K
Average Volume (3M)2.49M
Market Cap
$1.40M
Enterprise Value-$6.33M
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding345,123
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.70
Price to Sales (P/S)6.03
P/FCF Ratio-4.95
Enterprise Value/Market Cap-4.53
Enterprise Value/Revenue-0.71
Enterprise Value/Gross Profit1.94
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-18
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityMaterially lower debt and positive equity provide financial flexibility over the next 2–6 months, lowering restructuring/default risk and enabling management to fund commercial expansion and marketing without immediate aggressive deleveraging. This supports execution of distribution plans while losses narrow.
Regulatory/Product Differentiation (FDA-authorized VLN)Holding FDA authorization creates a durable competitive advantage vs. undifferentiated alternatives, reducing regulatory uncertainty and raising barriers to entry. This validation supports commercial adoption, retailer willingness to stock, and long-term product credibility versus competitors lacking similar approvals.
Sequential Revenue Growth And Retail TractionSequential top-line growth plus concrete retail distribution wins indicate early commercial scalability. Expanding shelf presence to thousands of outlets can drive sustainable unit volume gains, improve mix, and give the company leverage to convert marketing spend into repeat sales as execution risk is addressed.
Bears Say
Negative Gross Profit And Operating LossesSustained negative gross profit means core economics remain broken: until per-unit margins turn positive the company must rely on scale, pricing changes, or higher-margin products. Persistent operating losses lengthen the path to self-sufficiency and require continued external funding to bridge to break-even.
Negative Operating Cash Flow / Cash BurnOngoing negative operating and free cash flow constrains runway and limits the firm's ability to fund marketing and distribution from internal sources. This structural cash burn forces management to prioritize financing or rapid margin improvement, raising execution and liquidity risk over the medium term.
Reliance On Equity Financing And Dilution RiskFrequent capital actions (warrant inducement, reverse split, ATM prospectus) show dependence on equity markets for liquidity. This raises dilution risk and signals limited internal funding, which can weigh on long-term shareholder alignment and require careful execution to avoid repeated, value-eroding financings.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $3.74 and its highest was $2841.00 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $1.40M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 19, 2026 which is in 49 days.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$101.4 earnings per share for the quarter, missing the consensus estimate of N/A by -$101.4.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 345,123 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$101.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.344%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
XXII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.View all XXII earnings summariesTechnical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
73.39% Insiders
1.35% Mutual Funds
― Other Institutional Investors
25.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---